AAPL326.57+11.23 (+3.56%) ▲|ABBV255.00+4.09 (+1.63%) ▲|ABT103.46-1.77 (-1.68%) ▼|ACN177.87+2.07 (+1.18%) ▲|ADBE249.01-5.85 (-2.30%) ▼|AMAT456.75-12.10 (-2.58%) ▼|AMD505.31-15.79 (-3.03%) ▼|AMGN382.46-8.82 (-2.25%) ▼|AMT172.51-2.92 (-1.66%) ▼|AMZN251.64-0.76 (-0.30%) ▼|AVGO361.91-2.47 (-0.68%) ▼|AXP320.62-1.18 (-0.37%) ▼|BA204.88-1.55 (-0.75%) ▼|BAC62.50-0.18 (-0.28%) ▼|BKNG174.23+0.80 (+0.46%) ▲|BLK1,062.91-9.12 (-0.85%) ▼|BMY63.92-0.50 (-0.77%) ▼|BNY162.53+0.02 (+0.01%) ▲|BRK-B506.43-0.29 (-0.06%) ▼|C138.20+0.40 (+0.29%) ▲|CAT803.92-11.64 (-1.43%) ▼|CL87.93-0.10 (-0.11%) ▼|CMCSA25.19+0.60 (+2.44%) ▲|COF207.00-3.86 (-1.83%) ▼|COP137.45+0.92 (+0.67%) ▲|COST901.51-1.09 (-0.12%) ▼|CRM242.83-1.33 (-0.54%) ▼|CSCO107.85-1.58 (-1.44%) ▼|CVS95.44+0.06 (+0.06%) ▲|CVX213.10-0.72 (-0.33%) ▼|DE677.02-0.20 (-0.03%) ▼|DHR201.03-3.83 (-1.87%) ▼|DIS105.12+0.94 (+0.90%) ▲|DUK119.59-0.85 (-0.70%) ▼|EMR147.71-2.63 (-1.75%) ▼|FDX311.71+2.52 (+0.82%) ▲|GD354.24+1.57 (+0.45%) ▲|GE323.54-1.88 (-0.58%) ▼|GEV923.32-27.72 (-2.91%) ▼|GILD144.92-0.73 (-0.50%) ▼|GM85.87+2.11 (+2.52%) ▲|GOOG330.30+1.92 (+0.58%) ▲|GOOGL332.68+2.03 (+0.61%) ▲|GS1,017.64-11.14 (-1.08%) ▼|HD305.04-5.41 (-1.74%) ▼|HON201.98-2.95 (-1.44%) ▼|IBM233.73-6.21 (-2.59%) ▼|INTC101.00-5.24 (-4.93%) ▼|INTU311.98-1.96 (-0.63%) ▼|ISRG360.87+7.63 (+2.16%) ▲|JNJ266.59-0.49 (-0.18%) ▼|JPM353.02-1.69 (-0.48%) ▼|KO88.00+0.45 (+0.51%) ▲|LIN461.04-5.62 (-1.20%) ▼|LLY1,123.98-0.23 (-0.02%) ▼|LMT528.40+3.94 (+0.75%) ▲|LOW196.31-2.29 (-1.15%) ▼|LRCX299.98-15.86 (-5.02%) ▼|MA564.61-2.89 (-0.51%) ▼|MCD252.96-0.52 (-0.21%) ▼|MDLZ62.28-0.14 (-0.22%) ▼|MDT91.62-0.27 (-0.29%) ▼|META643.23-10.47 (-1.60%) ▼|MMM162.74-1.66 (-1.01%) ▼|MO68.57+0.68 (+1.00%) ▲|MRK144.69-2.85 (-1.93%) ▼|MS213.33-2.02 (-0.94%) ▼|MSFT490.76-0.90 (-0.18%) ▼|MU981.93-45.84 (-4.46%) ▼|NEE82.68+0.03 (+0.04%) ▲|NFLX75.86-0.17 (-0.22%) ▼|NKE36.59-0.76 (-2.03%) ▼|NOW131.14+0.03 (+0.02%) ▲|NVDA218.38-5.29 (-2.37%) ▼|ORCL153.94-7.69 (-4.76%) ▼|PEP136.87+0.18 (+0.13%) ▲|PFE27.53-0.26 (-0.92%) ▼|PG143.06+0.42 (+0.30%) ▲|PLTR165.70-3.83 (-2.26%) ▼|PM189.55+3.84 (+2.07%) ▲|QCOM177.81+1.41 (+0.80%) ▲|RTX197.47-0.08 (-0.04%) ▼|SBUX99.40-0.65 (-0.64%) ▼|SCHW107.06+0.52 (+0.48%) ▲|SO88.07-0.28 (-0.31%) ▼|SPG205.23+0.70 (+0.34%) ▲|T25.62+0.47 (+1.87%) ▲|TMO602.65-3.05 (-0.50%) ▼|TMUS176.76-0.58 (-0.33%) ▼|TSLA363.84-3.98 (-1.08%) ▼|TXN258.73-2.86 (-1.09%) ▼|UBER72.38+1.30 (+1.83%) ▲|UNH389.44-3.62 (-0.92%) ▼|UNP285.24+0.50 (+0.18%) ▲|UPS99.84+0.62 (+0.62%) ▲|USB62.24+0.13 (+0.20%) ▲|V367.19-0.20 (-0.05%) ▼|VZ49.91+0.17 (+0.33%) ▲|WFC89.12-0.56 (-0.62%) ▼|WMT105.81-0.02 (-0.02%) ▼|XOM165.50+1.27 (+0.77%) ▲|AAPL326.57+11.23 (+3.56%) ▲|ABBV255.00+4.09 (+1.63%) ▲|ABT103.46-1.77 (-1.68%) ▼|ACN177.87+2.07 (+1.18%) ▲|ADBE249.01-5.85 (-2.30%) ▼|AMAT456.75-12.10 (-2.58%) ▼|AMD505.31-15.79 (-3.03%) ▼|AMGN382.46-8.82 (-2.25%) ▼|AMT172.51-2.92 (-1.66%) ▼|AMZN251.64-0.76 (-0.30%) ▼|AVGO361.91-2.47 (-0.68%) ▼|AXP320.62-1.18 (-0.37%) ▼|BA204.88-1.55 (-0.75%) ▼|BAC62.50-0.18 (-0.28%) ▼|BKNG174.23+0.80 (+0.46%) ▲|BLK1,062.91-9.12 (-0.85%) ▼|BMY63.92-0.50 (-0.77%) ▼|BNY162.53+0.02 (+0.01%) ▲|BRK-B506.43-0.29 (-0.06%) ▼|C138.20+0.40 (+0.29%) ▲|CAT803.92-11.64 (-1.43%) ▼|CL87.93-0.10 (-0.11%) ▼|CMCSA25.19+0.60 (+2.44%) ▲|COF207.00-3.86 (-1.83%) ▼|COP137.45+0.92 (+0.67%) ▲|COST901.51-1.09 (-0.12%) ▼|CRM242.83-1.33 (-0.54%) ▼|CSCO107.85-1.58 (-1.44%) ▼|CVS95.44+0.06 (+0.06%) ▲|CVX213.10-0.72 (-0.33%) ▼|DE677.02-0.20 (-0.03%) ▼|DHR201.03-3.83 (-1.87%) ▼|DIS105.12+0.94 (+0.90%) ▲|DUK119.59-0.85 (-0.70%) ▼|EMR147.71-2.63 (-1.75%) ▼|FDX311.71+2.52 (+0.82%) ▲|GD354.24+1.57 (+0.45%) ▲|GE323.54-1.88 (-0.58%) ▼|GEV923.32-27.72 (-2.91%) ▼|GILD144.92-0.73 (-0.50%) ▼|GM85.87+2.11 (+2.52%) ▲|GOOG330.30+1.92 (+0.58%) ▲|GOOGL332.68+2.03 (+0.61%) ▲|GS1,017.64-11.14 (-1.08%) ▼|HD305.04-5.41 (-1.74%) ▼|HON201.98-2.95 (-1.44%) ▼|IBM233.73-6.21 (-2.59%) ▼|INTC101.00-5.24 (-4.93%) ▼|INTU311.98-1.96 (-0.63%) ▼|ISRG360.87+7.63 (+2.16%) ▲|JNJ266.59-0.49 (-0.18%) ▼|JPM353.02-1.69 (-0.48%) ▼|KO88.00+0.45 (+0.51%) ▲|LIN461.04-5.62 (-1.20%) ▼|LLY1,123.98-0.23 (-0.02%) ▼|LMT528.40+3.94 (+0.75%) ▲|LOW196.31-2.29 (-1.15%) ▼|LRCX299.98-15.86 (-5.02%) ▼|MA564.61-2.89 (-0.51%) ▼|MCD252.96-0.52 (-0.21%) ▼|MDLZ62.28-0.14 (-0.22%) ▼|MDT91.62-0.27 (-0.29%) ▼|META643.23-10.47 (-1.60%) ▼|MMM162.74-1.66 (-1.01%) ▼|MO68.57+0.68 (+1.00%) ▲|MRK144.69-2.85 (-1.93%) ▼|MS213.33-2.02 (-0.94%) ▼|MSFT490.76-0.90 (-0.18%) ▼|MU981.93-45.84 (-4.46%) ▼|NEE82.68+0.03 (+0.04%) ▲|NFLX75.86-0.17 (-0.22%) ▼|NKE36.59-0.76 (-2.03%) ▼|NOW131.14+0.03 (+0.02%) ▲|NVDA218.38-5.29 (-2.37%) ▼|ORCL153.94-7.69 (-4.76%) ▼|PEP136.87+0.18 (+0.13%) ▲|PFE27.53-0.26 (-0.92%) ▼|PG143.06+0.42 (+0.30%) ▲|PLTR165.70-3.83 (-2.26%) ▼|PM189.55+3.84 (+2.07%) ▲|QCOM177.81+1.41 (+0.80%) ▲|RTX197.47-0.08 (-0.04%) ▼|SBUX99.40-0.65 (-0.64%) ▼|SCHW107.06+0.52 (+0.48%) ▲|SO88.07-0.28 (-0.31%) ▼|SPG205.23+0.70 (+0.34%) ▲|T25.62+0.47 (+1.87%) ▲|TMO602.65-3.05 (-0.50%) ▼|TMUS176.76-0.58 (-0.33%) ▼|TSLA363.84-3.98 (-1.08%) ▼|TXN258.73-2.86 (-1.09%) ▼|UBER72.38+1.30 (+1.83%) ▲|UNH389.44-3.62 (-0.92%) ▼|UNP285.24+0.50 (+0.18%) ▲|UPS99.84+0.62 (+0.62%) ▲|USB62.24+0.13 (+0.20%) ▲|V367.19-0.20 (-0.05%) ▼|VZ49.91+0.17 (+0.33%) ▲|WFC89.12-0.56 (-0.62%) ▼|WMT105.81-0.02 (-0.02%) ▼|XOM165.50+1.27 (+0.77%) ▲|
30.6 C
New York
Thursday, September 10, 2026

Tag: patient

newssourceFORcompanyinformationcontent1releasesmarket

MALAYSIA HEALTHCARE TRAVEL COUNCIL LAUNCHES MYMT 2026, MALAYSIA’S FIRST MEDICAL TOURISM YEAR

KUALA LUMPUR, Malaysia, July 25, 2025 /PRNewswire/ -- The Malaysia Healthcare Travel Council (MHTC)  launched Malaysia Year of Medical Tourism (MYMT) 2026 today at the...

MALAYSIA HEALTHCARE TRAVEL COUNCIL LAUNCHES MYMT 2026, MALAYSIA’S FIRST MEDICAL TOURISM YEAR

KUALA LUMPUR, Malaysia, July 25, 2025 /PRNewswire/ -- The Malaysia Healthcare Travel Council (MHTC)  launched Malaysia Year of Medical Tourism (MYMT) 2026 today at the...

Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV Infection

Schlieren / Zurich, Switzerland, 25 July, 2025 – Memo Therapeutics AG ("MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announced results from its Phase II clinical trial evaluating potravitug, a highly potent human BK polyomavirus (“BKPyV”)-neutralizing monoclonal antibody, for the treatment of BKPyV infection in kidney transplant recipients (“KTR”).

Yali Capital Raises ₹893 Crores to Back India’s Deep Tech Revolution

BENGALURU, India, July 25, 2025 /PRNewswire/ -- Yali Capital, a SEBI-registered Category II Alternative Investment Fund (AIF), today announced the successful closure of its...

Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million

SHANGHAI, July 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and...

Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering

NANJING, China, July 25, 2025 /PRNewswire/ -- On 25 July, 2025 (China Time), Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company") listed on the...

Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering

NANJING, China, July 24, 2025 /PRNewswire/ -- On 25 July, 2025 (China Time), Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company") listed on the...

PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO

SAN JOSE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (“the Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that Larry L. Wood will join the Company as president and CEO effective September 2, 2025. Dr. Reza Zadno will retire as president, CEO, and director effective September 1, 2025.

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

Accesorios Reveals 150,000 Loyal Customers Built Through Six-Year Stealth Growth Strategy

Accesorios Ends Six-Year Stealth Operations, Reveals 150,000-Customer Base Built Through Word-of-Mouth

Dr. Joel Berley Launches 2026 Scholarship to Empower Aspiring Medical Leaders Nationwide

PLANTATION, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Dr. Joel Berley, a nationally respected oral surgeon and founder of Plantation Oral Surgery, is pleased to announce the official launch of the 2026 application cycle for the Dr. Joel Berley Scholarship for Future Doctors. This prestigious academic grant reflects Dr. Berley’s enduring mission to identify and uplift undergraduate students who are poised to become catalysts for progress in medicine.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatient

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers